Moderna, Inc. (NASDAQ: MRNA) saw its stock soar 5.33% in pre-market trading on Monday, as investors reacted positively to the company's announcement of its upcoming presentations at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress.
The biotechnology company revealed that it will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the prestigious conference in Vienna, Austria, from April 11-15, 2025. Moderna's strong presence at the event, with twelve scientific presentations including three oral presentations, demonstrates the breadth and depth of its research pipeline in respiratory and emerging infectious diseases.
The market's enthusiastic response to this news highlights the continued importance of Moderna's mRNA technology platform and its potential applications beyond COVID-19 vaccines. As the company strives to expand its portfolio and showcase its capabilities in addressing various infectious diseases, investors appear to be betting on Moderna's long-term growth prospects and its ability to maintain its position as a leader in mRNA-based medicines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.